Prevnar®

BIOLOGICAL5 trials

Sponsors

GlaxoSmithKline, Sinovac Life Sciences Co., Ltd.

Conditions

MeaslesMeasles-Mumps-Rubella VaccineMumpsPneumococcal Infectious DiseaseRubellaVaricella

Phase 1

Clinical Trial of PCV24 in Infants Aged 2-23 Months

RecruitingNCT06800261

Sinovac Life Sciences Co., Ltd.Pneumococcal Infectious Disease

Start: 2025-05-08End: 2026-06-01Target: 180Updated: 2026-01-28

Phase 2

Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age

CompletedNCT00578175

GlaxoSmithKlineMeasles, Mumps, Rubella +1

Start: 2007-11-20End: 2009-03-17Updated: 2018-10-09

Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age

CompletedNCT00861744

GlaxoSmithKlineMeasles, Measles-Mumps-Rubella Vaccine, Mumps +1

Start: 2009-06-03End: 2012-06-18Updated: 2020-01-03

Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years

RecruitingNCT07300644

Sinovac Life Sciences Co., Ltd.Pneumococcal Infectious Disease

Start: 2025-11-25End: 2027-12-31Target: 420Updated: 2025-12-24

Phase 3

Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine

RecruitingNCT06617715

Sinovac Life Sciences Co., Ltd.Pneumococcal Infectious Disease

Start: 2024-10-23End: 2026-07-30Target: 3080Updated: 2026-01-28

Related Papers

Two-year antibody persistence in children vaccinated at 12–15 months with a measles-mumps-rubella virus vaccine without human serum albumin

Human Vaccines & Immunotherapeutics2017-05-0811 citations

Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12-15 Months

Journal of the Pediatric Infectious Diseases Society2014-08-0720 citations